Education
About Us
Working with TipRanks
Follow Us
Protalix Biotherapeutics (PLX)
:PLX
PLX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.82 - $2.76
Previous CloseN/A
Volume368.29K
Average Volume (3M)724.72K
Market Cap
$197.42M
Enterprise Value$61.12M
Total Cash (Recent Filing)$37.81M
Total Debt (Recent Filing)$47.97M
Price to Earnings (P/E)96.2
Beta0.40
Next Earnings
May 09, 2025EPS Estimate
0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.03
Shares Outstanding78,032,585
10 Day Avg. Volume839,747
30 Day Avg. Volume724,716
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.64
Price to Cash Flow (P/CF)12.20
P/FCF Ratio12.20
Enterprise Value/Market Cap0.31
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit1.14
Enterprise Value/Ebitda-9.44
Forecast
1Y Price Target
$15.00Price Target Upside504.84% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Protalix News
PremiumCompany Announcements
Protalix BioTherapeutics Reports Record Revenue and Clinical Progress
PremiumCompany Announcements
Protalix BioTherapeutics Reports Strong Revenue Amid Challenges
PremiumCompany Announcements
Protalix Achieves Key Milestones and Remains Debt-Free---
Ownership Overview
4.29% Insiders
0.90% Mutual Funds
0.97% Other Institutional Investors
93.63% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PLX FAQ
What was Protalix Biotherapeutics’s price range in the past 12 months?
Protalix Biotherapeutics lowest stock price was $0.82 and its highest was $2.76 in the past 12 months.
What is Protalix Biotherapeutics’s market cap?
Protalix Biotherapeutics’s market cap is $197.42M.
When is Protalix Biotherapeutics’s upcoming earnings report date?
Protalix Biotherapeutics’s upcoming earnings report date is May 09, 2025 which is in 43 days.
How were Protalix Biotherapeutics’s earnings last quarter?
Protalix Biotherapeutics released its earnings results on Mar 17, 2025. The company reported $0.1 earnings per share for the quarter, beating the consensus estimate of $0.07 by $0.03.
Is Protalix Biotherapeutics overvalued?
According to Wall Street analysts Protalix Biotherapeutics’s price is currently Undervalued.
Does Protalix Biotherapeutics pay dividends?
Protalix Biotherapeutics does not currently pay dividends.
What is Protalix Biotherapeutics’s EPS estimate?
Protalix Biotherapeutics’s EPS estimate is 0.03.
How many shares outstanding does Protalix Biotherapeutics have?
Protalix Biotherapeutics has 78,032,585 shares outstanding.
What happened to Protalix Biotherapeutics’s price movement after its last earnings report?
Protalix Biotherapeutics reported an EPS of $0.1 in its last earnings report, beating expectations of $0.07. Following the earnings report the stock price went up 9.375%.
Which hedge fund is a major shareholder of Protalix Biotherapeutics?
Currently, no hedge funds are holding shares in PLX
---
Protalix Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$15.00 (504.84% Upside)
$15.00 (504.84% Upside)
Hedge Fund Trend
Decreased
By 2.4M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.6%
Last 30 Days ▲ 6.5%
Last 30 Days ▲ 6.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
107.37%
12-Months-Change
Fundamentals
Return on Equity
7.64%
Trailing 12-Months
Asset Growth
-13.05%
Trailing 12-Months
Company Description
Protalix Biotherapeutics
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in the last stage of clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is based in Hackensack, New Jersey.
---
PLX Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Protalix demonstrated strong revenue growth and successfully completed a Phase 1 trial for PRX-115, but faced challenges with decreased R&D service revenues and lower net income.Read More>---
PLX Stock 12 Month Forecast
Average Price Target
$15.00
▲(504.84% Upside)
Technical Analysis
Amicus
―
Arrowhead Pharmaceuticals
―
BioMarin Pharmaceutical
―
Ultragenyx Pharmaceutical
―
Crispr Therapeutics AG
―
Best Analysts Covering PLX
1 Year
1 Year Success Rate
2/3 ratings generated profit
1 Year Average Return
-8.20%
reiterated a buy rating 2 months ago
Copying Ram Selvaraju's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of -8.20% per trade.
---